RecruitingEarly Phase 1NCT06610682

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Studying Glial tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Principal Investigator
Karisa Schreck, MD, MD
Johns Hopkins University
Intervention
Plixorafenib(drug)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (1)

Collaborators

Fore Biotherapeutics · Ivy Brain Tumor Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06610682 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor

← Back to all trials